|
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h
|
Homo sapiens
|
0.4
ug.mL-1
|
|
|
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h
|
Homo sapiens
|
8.5
ug.mL-1
|
|
|
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay
|
Homo sapiens
|
0.6
ug.mL-1
|
|
|
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
|
Percent inhibition of [3H]-thymidine incorporation was determined in human chronic myelogenous leukemic K-562 cell line at 10 ug/mL after 48 hr
|
Homo sapiens
|
80.0
%
|
|
|
Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
|
Mus musculus
|
24.0
nM
|
|
|
Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
|
Mus musculus
|
20.0
nM
|
|
|
Percent inhibition of Ehrlich ascites carcinoma growth at 200 mg/kg per day
|
Mus musculus
|
99.6
%
|
|
|
Percentage inhibition as antitumor activity in carcinoma CF1 male mice.
|
Mus musculus
|
99.9
%
|
|
|
Antitumor activity in CF1 mice bearing Ehrlich ascites carcinoma measured as percentage inhibition at 50 mg/kg
|
Mus musculus
|
96.3
%
|
|
|
Antiproliferative activity against human MT4 cells by MTT assay
|
Homo sapiens
|
100.0
nM
|
|
|
Cytotoxicity against human KB cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.55
ug.mL-1
|
|
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.7
ug.mL-1
|
|
|
Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.26
ug.mL-1
|
|
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.8
ug.mL-1
|
|
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.87
ug.mL-1
|
|
|
Cytotoxicity against human NSCLC-N6 cells after 72 hrs by MTT assay
|
Homo sapiens
|
0.79
ug.mL-1
|
|
|
In vivo antineoplastic activity against mouse Ehrlich ascite carcinoma cells xenografted in CF1 mouse assessed as inhibition of tumor growth at 0.5 mg/kg/day after 9 days relative to control
|
Mus musculus
|
99.9
%
|
|
|
Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay
|
Homo sapiens
|
51.7
ug.mL-1
|
|
|
Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay
|
Homo sapiens
|
12.3
ug.mL-1
|
|
|
Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay
|
Homo sapiens
|
1.1
ug.mL-1
|
|
|
Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay
|
Mus musculus
|
61.0
ug.mL-1
|
|
|
Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay
|
Mus musculus
|
3.6
ug.mL-1
|
|
|
Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.5
ug.mL-1
|
|
|
Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay
|
Mus musculus
|
83.0
ug.mL-1
|
|
|
Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay
|
Mus musculus
|
42.0
ug.mL-1
|
|
|
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay
|
Mus musculus
|
2.7
ug.mL-1
|
|
|
Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay
|
Mus musculus
|
37.0
ug.mL-1
|
|
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
|
Mus musculus
|
2.1
ug.mL-1
|
|
|
Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay
|
Mus musculus
|
0.3
ug.mL-1
|
|
|
Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
|
Mus musculus
|
1.3
ug.mL-1
|
|
|
Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay
|
Mus musculus
|
3.0
nM
|
|
|
Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay
|
Homo sapiens
|
7.0
nM
|
|
|
Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay
|
Mus musculus
|
15.0
nM
|
|
|
Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
|
Mus musculus
|
1.3
ug.mL-1
|
|
|
Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay
|
Rattus norvegicus
|
30.2
ug.mL-1
|
|
|
Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method
|
Mus musculus
|
3.0
nM
|
|
|
Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method
|
Homo sapiens
|
7.0
nM
|
|
|
Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method
|
Mus musculus
|
17.0
nM
|
|
|
Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay
|
Mus musculus
|
3.0
nM
|
|
|
Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay
|
Homo sapiens
|
7.0
nM
|
|
|
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
|
Mus musculus
|
15.0
nM
|
|
|
Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay
|
Mus musculus
|
3.0
nM
|
|
|
Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay
|
Homo sapiens
|
7.0
nM
|
|
|
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
|
Mus musculus
|
15.0
nM
|
|
|
Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days
|
Homo sapiens
|
149.5
nM
|
|
|
Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay
|
Mus musculus
|
0.0025
ug.mL-1
|
|
|
Cytotoxicity against HEK293 cells by rapid colorimetric assay
|
Homo sapiens
|
0.00071
ug.mL-1
|
|
|
Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay
|
Mus musculus
|
0.0051
ug.mL-1
|
|
|
Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay relative to LPS
|
Mus musculus
|
31.8
%
|
|
|
Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 10 ug/ml after 72 hrs by MTT assay relative to LPS
|
Mus musculus
|
38.0
%
|
|
|
Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 1 ug/ml after 72 hrs by MTT assay relative to LPS
|
Mus musculus
|
44.1
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
107.78
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
105.34
%
|
|
|
Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor growth inhibition at 20 mg/kg, ip qd for 7 days (Rvb = 0%)
|
Mus musculus
|
99.6
%
|
|
|
Antitumor activity against mouse EAC allografted in CF1 mouse assessed as inhibition of tumor growth at 33 mg/kg/day measured on day 7
|
Mus musculus
|
99.6
%
|
|
|
Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC
|
Homo sapiens
|
0.5
%
|
|
|
PubChem BioAssay. RKO viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)
|
None
|
659.1
nM
|
|
|
PubChem BioAssay. HCT116 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)
|
None
|
259.1
nM
|
|
|
PubChem BioAssay. VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50. (Class of assay: confirmatory)
|
None
|
914.9
nM
|
|
|
PubChem BioAssay. HT-29 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)
|
None
|
634.55
nM
|
|
|
PubChem BioAssay. DLD-1 viability from Cell TiterGlo-IC50. (Class of assay: confirmatory)
|
None
|
259.81
nM
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
22.75
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
6.85
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
7.84
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
11.75
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
19.41
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
11.25
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-0.87
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
3.56
%
|
|
|
Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 50 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control
|
Rattus norvegicus
|
28.0
%
|
|
|
Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 50 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control
|
Rattus norvegicus
|
26.0
%
|
|
|
Inhibition of UDPGDH in rat hepatocytes assessed as increase in unconjugated bilirubin level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control
|
Rattus norvegicus
|
19.0
%
|
|
|
Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control
|
Rattus norvegicus
|
19.0
%
|
|
|
Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control
|
Rattus norvegicus
|
12.0
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
-11.49
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.14
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.14
%
|
|
